Biomarin Pharmaceutical Inc

Pharmaceutical company · Novato, California, United States · Nasdaq: BMRN

Biomarin Pharmaceutical Inc is a pharmaceutical company headquartered in Novato, California, United States. Its shares trade on Nasdaq under the ticker BMRN. The US FDA lists 1 drug manufacturing or testing site registered to the company. It has received 3 US government small-business research awards (SBIR/STTR) from health agencies, $286,641 in total, most recently in 2001.

Profile compiled from public records. Is this your company? Request a correction or update

Biomarin Pharmaceutical at a glance

Typepharmaceutical company
HeadquartersNovato, California, United States
Stock listingNasdaq: BMRN
SEC industryPharmaceutical Preparations
FDA-registered sites1
SEC CIK1048477

What does Biomarin Pharmaceutical do?

Operations at its FDA-registered drug sites

AnalysisAPI manufacturingLabelingManufacturing

US government research funding

3 SBIR/STTR small-business research awards from US health agencies, $286,641 in total (1998 to 2001).

Where is Biomarin Pharmaceutical located?

Headquarters: Novato, California, United States

  • Novato, CaliforniaBioMarin Pharmaceutical Inc. · FDA drug site

Frequently asked questions about Biomarin Pharmaceutical

Where is Biomarin Pharmaceutical headquartered?

Biomarin Pharmaceutical Inc is headquartered in Novato, California, United States.

What does Biomarin Pharmaceutical do?

Biomarin Pharmaceutical Inc is a pharmaceutical company. Its FDA-registered drug sites are registered for analysis, API manufacturing, labeling and manufacturing. Its SEC industry classification is Pharmaceutical Preparations.

Is Biomarin Pharmaceutical a public company?

Yes. Biomarin Pharmaceutical Inc trades on Nasdaq under the ticker BMRN.

Similar companies

Need a CRO or CDMO for your next study?

Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.

Compare quotes

Sources

Location data: GeoNames (geonames.org), CC BY 4.0.

Last updated 2026-09-23.